Faced with many regulatory bottlenecks, the European cell therapy community must unite and confront these challenges head-on. The 3rd Cell Therapy Analytical Development Summit Europe is your unmissable opportunity to connect with peers, share pain points and establish analytical standards for smoother interactions with regulatory bodies including the FDA, EMA and MHRA.

Join analytical development and quality control experts from industry-leaders like Achilles Therapeutics, Avobis Bio, Bristol Myers Squibb, Johnson and Johnson, GSK, MHRA, to tackle challenges from product characterisation to method validation and release preparation.

Seize the chance this September to collaborate, connect and share insights to drive the future development of potent, safe and effective autologous and allogeneic cell therapies forward!




Conference + 2 Workshops – Drug Developer Pricing: GBP 2997.00,
Conference + 1 Workshops – Drug Developer Pricing: GBP 2598.00,
Conference Only – Drug Developer Pricing: GBP 2199.00,
Conference + 2 Workshops – Standard Pricing: GBP 4297.00,
Conference + 1 Workshop – Standard Pricing: GBP 3698.00,
Conference Only – Standard Pricing: GBP 3099.00,
Conference + 2 Workshops – Academic Pricing: GBP 2397.00,
Conference + 1 Workshop – Academic Pricing: GBP 2098.00,
Conference Only – Academic Pricing: GBP 1799.00

Speakers: Alison Caldwell, Group Lead, Analytical Development, Resolution Therapeutics, Amanda Versteilen, Associate Director Analytical QC, Bristol Myers Squibb, Andreea Iftimia Mander, Head of Analytical and Biological Sciences, Medicines and Healthcare products Regulatory Agency, Arindam Mitra, Director, CMC, Leucid Bio, Aurelien Bunga, Senior Scientist, Rinri Therapeutics, Benjamin Espen, Principal Quality Engineer, Avobis Bio, Diego Vazquez Rodriguez, Senior Manager QC Analytics Cell Therapy, Bristol Myers Squibb, Fredrik Wallberg, Flow Cytometry Coordinator, Quell Therapeutics, Ilaria Santeramo, Group Leader, Analytical Development, Resolution Therapeutics, Ilaria Visigalli, Research Lead, Study Director, GLP SR-Tiget, Jas Uppal, Regulatory Consultant, Gamida Cell, Matthijs Koorevaar, Director, Quality Control, Advanced Therapies Platform, Johnson and Johnson, Minh Ngoc Duong, Senior Analytical Scientist, Tigen Pharma, Rebecca Moore, Head Of Quality Control, Achilles Therapeutics, Sharon Longhurst, Principal Consultant, Advanced Biologics Consulting, Shayoni Dutta, Senior Principal Scientist, GSK, Vinoy Ramachandran, Head of Bioinformatics, Medicines and Healthcare products Regulatory Agency